Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects

被引：8

作者：

Kim, Kyeong Min ^{[1
]}

Hwang, Na-Hee ^{[1
]}

Hyun, Ja-Shil ^{[1
]}

Shin, Dongyun ^{[1
]}

机构：

[1] Gachon Univ, Coll Pharm, Hambakmoe Ro 191, Incheon 21935, South Korea

来源：

MOLECULES | 2024年 / 29卷 / 10期

基金：

新加坡国家研究基金会;

关键词：

interleukin receptor-associated kinase (IRAK) proteins; inhibitor; degrader; immunity; SIGNALING MEDIATOR; KINASE IRAK; INNATE; ACTIVATION; INFLAMMATION; INHIBITORS; FAMILY; NEUROINFLAMMATION; IDENTIFICATION; MICRORNA-146A;

D O I：

10.3390/molecules29102226

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Interleukin receptor-associated kinase (IRAK) proteins are pivotal in interleukin-1 and Toll-like receptor-mediated signaling pathways. They play essential roles in innate immunity and inflammation. This review analyzes and discusses the physiological functions of IRAK1 and its associated diseases. IRAK1 is involved in a wide range of diseases such as dry eye, which highlights its potential as a therapeutic target under various conditions. Various IRAK1 inhibitors, including Pacritinib and Rosoxacin, show therapeutic potential against malignancies and inflammatory diseases. The covalent IRAK1 inhibitor JH-X-119-01 shows promise in B-cell lymphomas, emphasizing the significance of covalent bonds in its activity. Additionally, the emergence of selective IRAK1 degraders, such as JNJ-101, provides a novel strategy by targeting the scaffolding function of IRAK1. Thus, the evolving landscape of IRAK1-targeted approaches provides promising avenues for increasingly safe and effective therapeutic interventions for various diseases.

引用

页数：17

共 100 条

[1] IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival [J].

Adams, Allie K. ;

Bolanos, Lyndsey C. ;

Dexheimer, Phillip J. ;

Karns, Rebekah A. ;

Aronow, Bruce J. ;

Komurov, Kakajan ;

Jegga, Anil G. ;

Casper, Keith A. ;

Patil, Yash J. ;

Wilson, Keith M. ;

Starczynowski, Daniel T. ;

Wells, Susanne I. .

ONCOTARGET, 2015, 6 (41) :43395-43407

[2] Insights into pharmacological mechanisms of polydatin in targeting risk factors -mediated atherosclerosis [J].

Ahmad, Parvej ;

Alvi, Sahir Sultan ;

Iqbal, Danish ;

Khan, M. Salman .

LIFE SCIENCES, 2020, 254

[3] Toll-like receptors: critical proteins linking innate and acquired immunity [J].

Akira, S ;

Takeda, K ;

Kaisho, T .

NATURE IMMUNOLOGY, 2001, 2 (08) :675-680

[4] Targeting Neuroinflammation to Treat Alzheimer's Disease [J].

Ardura-Fabregat, A. ;

Boddeke, E. W. G. M. ;

Boza-Serrano, A. ;

Brioschi, S. ;

Castro-Gomez, S. ;

Ceyzeriat, K. ;

Dansokho, C. ;

Dierkes, T. ;

Gelders, G. ;

Heneka, Michael T. ;

Hoeijmakers, L. ;

Hoffmann, A. ;

Iaccarino, L. ;

Jahnert, S. ;

Kuhbandner, K. ;

Landreth, G. ;

Lonnemann, N. ;

Loeschmann, P. A. ;

McManus, R. M. ;

Paulus, A. ;

Reemst, K. ;

Sanchez-Caro, J. M. ;

Tiberi, A. ;

Van der Perren, A. ;

Vautheny, A. ;

Venegas, C. ;

Webers, A. ;

Weydt, P. ;

Wijasa, T. S. ;

Xiang, X. ;

Yang, Y. .

CNS DRUGS, 2017, 31 (12) :1057-1082

[5] Toll-Like Receptor 4 Stimulation Initiates an Inflammatory Response That Decreases Cardiomyocyte Contractility [J].

Avlas, Orna ;

Fallach, Reut ;

Shainberg, Asher ;

Porat, Eyal ;

Hochhauser, Edith .

ANTIOXIDANTS & REDOX SIGNALING, 2011, 15 (07) :1895-1909

[6] Understanding early TLR signaling through the Myddosome [J].

Balka, Katherine R. ;

De Nardo, Dominic .

JOURNAL OF LEUKOCYTE BIOLOGY, 2019, 105 (02) :339-351

[7] IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies [J].

Bennett, Joshua ;

Starczynowski, Daniel T. .

CURRENT OPINION IN HEMATOLOGY, 2022, 29 (01) :8-+

[8] Severe COVID-19: what have we learned with the immunopathogenesis? [J].

Bordallo, Bruno ;

Bellas, Mozart ;

Cortez, Arthur Fernandes ;

Vieira, Matheus ;

Pinheiro, Marcelo .

ADVANCES IN RHEUMATOLOGY, 2020, 60 (01)

[9] The inflammatory response in sepsis [J].

Bosmann, Markus ;

Ward, Peter A. .

TRENDS IN IMMUNOLOGY, 2013, 34 (03) :129-136

[10] IRAK-4 inhibitors. Part 1: A series of amides [J].

Buckley, George M. ;

Gowers, Lewis ;

Higueruelo, Alicia Perez ;

Jenkins, Kerry ;

Mack, Stephen R. ;

Morgan, Trevor ;

Parry, David M. ;

Pitt, William R. ;

Rausch, Oliver ;

Richard, Marianna D. ;

Sabin, Verity ;

Fraser, Joanne L. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (11) :3211-3214

← 1 2 3 4 5 6 7 8 9 10 →